ep ahead reduc guid
ep top consensu ep beat
better revenu profit factor line ad
temper ep guidanc midpoint
vs consensu owe continu challeng pharmedium
reduc ep reflect beat
off-set pharmedium woe memphi facil remain
shutter tp move lower view
larg custom relationship specialti oncolog
reiter outperform share fell recent high
decemb vs broader regulatory/drug price concern
view share may edg higher suspect better
encourag guidanc call lsd vs previou
lsd msd dist op profit growth larg point pharmedium
culprit await detail underli dist profit call well
updat segment dynam mwi/vca win view
well posit amongst distributor given focu non-tradit
busi pharmedium challeng wane view premium
valuat ev/ebitda peer
warrant given revenu profit driver wba matur pharmaci
relationship onboard esrx relationship contribut
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
global pharmaceut sourc
price jan rate outperform target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
revenu prevail profit mix revenu growth vs estimate
distribut incl specialti acquisit rise vs estimate despit
pharmedium challeng rose healthi slightli plan
repres profit compon posit thesi gross margin
bp bp plan op expens bp bp higher plan
ebit margin fell bp slightli plan focu area op profit dist
sank well aggress estimate like pharmedium
gener million cash fund million share repurchas
compani mention price
